Access to peginterferon plus ribavirin therapy for hepatitis C in Romania between 2002-2009.
BACKGROUND
An overall prevalence rate of HCV infection in Romanian adult population was recently estimated to be 3.23%. The proportion of treated patients with chronic hepatitis C in our country has never been assessed.


OBJECTIVE
1) to analyze the quality and quantity of antiviral therapy delivery; 2) to determine the proportion of patients being annually and ever treated with antiviral therapy in Romania and 3) to identify barriers against treatment of HCV infected-population in Romania.


RESULTS
The number of annually treated patients remained relatively stable between 2002 and 2007 (1,813 patients treated with pegylated interferon and ribavirin in 2002 and 2,446 in 2007). There was a doubled increase in reimbursed treatment in 2008 and 2009 (4,503 and respectively 4,701 treated patients) due to a special campaign organized to increase awareness and prevention of HCV transmission. The median time to therapy approval varies from county to county; overall it is 10.23 months. A total number of 25,318 patients with chronic C hepatitis were treated between 2002-2009, corresponding to a cumulative proportion of 4.1% of the prevalent cases of HCV infection treated in Romania until 1st January 2010. The main limiting factor of access to antiviral therapy for hepatitis C in Romania remains the lack of funds.


CONCLUSIONS
This is the first analysis of the nationwide practice for treatment of hepatitis C in Romania. Increased public health efforts are required to improve access to antiviral therapy for hepatitis C in Romania.
Gheorghe
Liana
L
Center of Gastroenterology and Hepatology, Fundeni Clinical Institute of Digestive Diseases and Liver Transplantation, Bucharest, Romania. drgheorghe@xnet.ro
Pascu
Oliviu
O
Ceausu
Emanoil
E
Csiki
Irma Eva
IE
Iacob
Speranta
S
Caruntu
Florin
F
Simionov
Iulia
I
Vadan
Roxana
R
D000998:Antiviral Agents / Q000191:economics / Q000627:therapeutic use*; D001364:Awareness; D016527:Drug Costs / Q000639:trends; D004359:Drug Therapy, Combination; D007722:Health Knowledge, Attitudes, Practice; D006293:Health Promotion; D006297:Health Services Accessibility / Q000191:economics / Q000639:trends*; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology / Q000635:transmission; D006801:Humans; D007349:Insurance, Health, Reimbursement / Q000639:trends; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000191:economics / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000191:economics / Q000627:therapeutic use*; D010818:Practice Patterns, Physicians' / Q000191:economics / Q000639:trends*; D011994:Recombinant Proteins; D012017:Referral and Consultation / Q000639:trends; D012254:Ribavirin / Q000191:economics / Q000627:therapeutic use*; D012383:Romania / Q000453:epidemiology; D013997:Time Factors
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a